<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00142298</url>
  </required_header>
  <id_info>
    <org_study_id>CLDT600A2303</org_study_id>
    <secondary_id>NV-02B-022</secondary_id>
    <nct_id>NCT00142298</nct_id>
  </id_info>
  <brief_title>Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies</brief_title>
  <official_title>An Open Label Trial of Telbivudine (LdT) in Adults With Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This trial is being conducted as an open-label, extended-term study for patients with chronic
      hepatitis B who have previously completed an Idenix-sponsored trial with telbivudine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients from 6 feeder trials could be eligible to enter current study CLDT600A2303 (
      NCT00142298) if they met inclusion/exclusion criteria. The feeder studies were as follows:

        -  CLDT600A2302 (NV-02B-007)(NCT00057265), the GLOBE study, was a Phase III, randomized,
           doubleblind,multi-center, 104-week, pivotal study of telbivudine vs. lamivudine in
           treatment of naïve patients with compensated chronic hepatitis B.
           CLDT600A2302/NV-02B-007 (NCT00057265) is hereafter referred to as study 2302.

        -  NV-02B-015 (NCT00131742) was a Phase III, randomized, double-blind, 104-week study
           comparing the efficacy and safety of telbivudine (600 mg/day) to lamivudine (100 mg/day)
           in treatment of naïve Chinese patients with compensated chronic hepatitis B. NV-02B-015
           (NCT00131742) is hereafter referred to as study 015.

        -  CLDT600A2301 (NV-02B-011)(NCT00076336) was a Phase III, randomized double-blind,
           multi-center, 104-week, pivotal study of telbivudine (600 mg/day) vs. lamivudine (100
           mg/day) in treatment-naïve adults with decompensated chronic hepatitis B.
           CLDT600A2301/NV-02B-011 (NCT00076336) is hereafter referred to as study 2301.

        -  NV-02B-010 (NCT00124241) was a Phase IIb, 104-week extension study of telbivudine,
           lamivudine or the combination of both agents in patients with chronic hepatitis B who
           had completed the core study NV-02B-003 (NCT00124241). NV-02B-010 (NCT00124241) is
           hereafter referred to as study 010.

      NV-02B-003 (NCT00124241) was a Phase IIa, 52-week study of telbivudine, lamivudine or the
      combination of both agents in patients with HBeAg-positive chronic hepatitis B.

        -  CLDT600A2401 (NV-02B-018) (NCT00115245) was a Phase IIIb, randomized, open-label,
           multi-center,52-week study of telbivudine vs. adefovir dipivoxil for 24 weeks then a
           switch to telbivudine for another 28 weeks in treatment-naïve patients with compensated
           chronic hepatitis B. CLDT600A2401/NV-02B-018 (NCT00115245) is hereafter referred to as
           study 2401.

        -  CLDT600A2402 (NV-02B-019) (NCT00132652) was a Phase IIIb, randomized, open-label,
           multi-center, 52-week study of switching lamivudine to telbivudine vs. continued on
           lamivudine treatment in adults with compensated chronic hepatitis B who were previously
           treated with lamivudine for 3-12 months. CLDT600A2402/NV-02-019 (NCT00132652) is
           hereafter referred to as study 2402.

      PATIENT GROUPS:

      GROUP A: Patients with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B who did not
      discontinue treatment in their previous study due to an efficacy response and required
      further treatment or who had met the criteria for discontinuation of treatment in their
      previous study due to efficacy, but were being maintained on study drug by the principal
      investigator. For patients treated with telbivudine who enrolled into Group A from studies
      2302 and 015, the total telbivudine treatment time (starting from feeder study baseline to
      the end of the on-treatment period in study 2303) was 208 weeks. For patients treated with
      lamivudine in studies 2302/015 and enrolled into group A and for all patients in group A from
      studies 2401/2402/010, the total telbivudine treatment time was 104 weeks.

      GROUP B: Patients with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B who did not
      discontinue treatment in their previous study due to an efficacy response and required
      further treatment. Patients treated with telbivudine in study 2301 were enrolled to group B
      and the total telbivudine treatment time (starting from feeder study baseline to the end of
      the on-treatment period in study 2303) was 208 weeks. For patients treated with lamivudine in
      study 2301 and enrolled into group B, the total telbivudine treatment time was 104 weeks.

      GROUP C: Patients with either compensated or decompensated chronic hepatitis B, who had
      discontinued study drug treatment in their previous Idenix-sponsored study due to an efficacy
      response as recommended by protocol. Patients who were eligible for treatment discontinuation
      in their previous study but who were, at the principal investigators discretion, continued on
      study therapy, were eligible to enter this study in Group C provided their treatment was
      discontinued at their last visit of the previous study. The feeder studies for group C of
      current study were study 2302/015, 2401, 2402, and 010. For patients who enrolled into group
      C, total telbivudine treatment time was 104 weeks starting from the baseline of the feeder
      studies to their last visit of the feeder studies. Patients were enrolled to current study
      (study 2303) for off-treatment follow-up after the treatment discontinuation due to efficacy.
      Hence, patients did not receive any study drug except in case of patients who relapsed and
      reinitiated treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Maintained Therapeutic Response [Group A: LdT Pool 2302/015]</measure>
    <time_frame>156 weeks, 208 weeks (from feeder study baseline)</time_frame>
    <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Maintained Therapeutic Response [Group A: LAM Pool 2302/015]</measure>
    <time_frame>52 weeks, 104 weeks</time_frame>
    <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Maintained Therapeutic Response [Group A: Feeder Studies 2401/2402/010]</measure>
    <time_frame>52 weeks, 104 weeks</time_frame>
    <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Maintained Clinical Response [Group B: LdT 2301]</measure>
    <time_frame>156 weeks, 208 weeks (from feeder study baseline)</time_frame>
    <description>Maintained clinical response is defined as achievement of serum HBV DNA &lt; 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient's baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Maintained Clinical Response [Group B: LAM 2301]</measure>
    <time_frame>52 weeks,104 weeks</time_frame>
    <description>Maintained clinical response is defined as achievement of serum HBV DNA &lt; 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient's baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Therapeutic Response [Group C: LdT Pool and LAM Pool (2302/015)]</measure>
    <time_frame>52 weeks,104 weeks</time_frame>
    <description>The primary efficacy endpoint for Group C patients was the percentage of patients with sustained therapeutic response (defined as HBV DNA &lt; 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Therapeutic Response [Group C: Other Feeder Studies]</measure>
    <time_frame>52 weeks,104 weeks</time_frame>
    <description>The primary efficacy endpoint for Group C (other feeder studies) was the percentage of patients with sustained therapeutic response (defined as HBV DNA &lt; 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up.
Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive study drug except in case of patients who relapsed and reinitiated treatment. No statistical summary was performed , only patient listing was generated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Longitudinally Assess the Longer-term Antiviral Efficacy Achieved With Telbivudine Treatment</measure>
    <time_frame>52 weeks, 104 weeks, 156 weeks, 208 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Longitudinally Assess the Clinical Efficacy of Longer-term Treatment With Telbivudine</measure>
    <time_frame>52 weeks, 104 weeks, 156 weeks, 208 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Longitudinally Assess the Durability of HBeAg Responses Achieved With Telbivudine Treatment and Other Previous Treatments in Patients</measure>
    <time_frame>52 weeks, 104 weeks, 156 weeks, 208 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Longitudinal Frequency of Virologic Breakthrough and Characterize the Associated Mutations in the HBV Polymerase Gene in HBV DNA Amplified From Sera of Patients With Virologic Breakthrough</measure>
    <time_frame>52 weeks, 104 weeks, 156 weeks, 208 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1869</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine (LdT)</intervention_name>
    <description>Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.</description>
    <other_name>Sebivo®/Tyzeka®</other_name>
    <other_name>LdT600</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient completed a previous qualifying Idenix-Sponsored trial with telbivudine

          -  Patient was not discontinued from previous Idenix-Sponsored study

        Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Patient is pregnant or breastfeeding

          -  Patient is co-infected with hepatitis C, hepatitis D or HIV

        Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelburg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Dehli</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santurce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>TR-34353</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <results_first_submitted>January 12, 2011</results_first_submitted>
  <results_first_submitted_qc>June 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2011</results_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>An open-label trial of telbivudine in adults with chronic hepatitis B previously treated in Idenix-sponsored telbivudine studies. Study start March 2005 and completed November 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A : LdT Pool 2302/015</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks. The total telbivudine treatment time starting from feeder study baseline to the end of the on-treatment period in study 2303 was 208 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Group A : LAM Pool 2302/015</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Lamivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Group A: Feeder Study 2401</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase IIIb, registration study CLDT600A2401 (NCT00115245) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Group A: Feeder Study 2402</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase IIIb, registration study CLDT600A2402 (NCT00132652) and treated with Lamivudine or Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Group A: Feeder Study 010</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B were from phase IIb study NV-02B-010 (NCT00124241) of telbivudine, lamivudine or the combination of both agents. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Group B: LdT 2301</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B from phase III pivotal, registration study 2301 (NCT00076336) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks. The total telbivudine treatment time starting from feeder study baseline to the end of the on-treatment period in study 2303 was 208 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Group B: LAM 2301</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B from phase III pivotal, registration studies 2301 (NCT00076336) treated with Lamivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Group C: LdT Pool 2302/015</title>
          <description>Subjects with either compensated or decompensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Telbivudine. Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
        <group group_id="P9">
          <title>Group C: LAM Pool 2302/015</title>
          <description>Subjects with either compensated or decompensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Lamivudine. Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
        <group group_id="P10">
          <title>Group C: Other Feeder Studies</title>
          <description>Patients with either compensated or decompensated chronic hepatitis B, from 2401 (NCT00115245), 2402 (NCT00132652) and 010 (NCT00124241). Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="667"/>
                <participants group_id="P2" count="632"/>
                <participants group_id="P3" count="123"/>
                <participants group_id="P4" count="206"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="66"/>
                <participants group_id="P9" count="57"/>
                <participants group_id="P10" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="655"/>
                <participants group_id="P2" count="626"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="206"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="66"/>
                <participants group_id="P9" count="57"/>
                <participants group_id="P10" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="635"/>
                <participants group_id="P2" count="606"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="202"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="64"/>
                <participants group_id="P9" count="56"/>
                <participants group_id="P10" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="507">Completed week 104/week 208.</participants>
                <participants group_id="P2" count="456"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="121"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="58"/>
                <participants group_id="P9" count="52"/>
                <participants group_id="P10" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="85"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient, Investigator,or Sponsor request</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Virologic breakthrough</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other- not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A : LdT Pool 2302/015</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks. The total telbivudine treatment time starting from feeder study baseline to the end of the on-treatment period in study 2303 was 208 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Group A : LAM Pool 2302/015</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Lamivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Group A: Feeder Study 2401</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase IIIb, registration study CLDT600A2401 (NCT00115245) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Group A: Feeder Study 2402</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase IIIb, registration study CLDT600A2402 (NCT00132652) and treated with Lamivudine or Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Group A: Feeder Study 010</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B were from phase IIb study NV-02B-010 (NCT00124241) of telbivudine, lamivudine or the combination of both agents. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Group B: LdT 2301</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B from phase III pivotal, registration study 2301 (NCT00076336) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks. The total telbivudine treatment time starting from feeder study baseline to the end of the on-treatment period in study 2303 was 208 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Group B: LAM 2301</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B from phase III pivotal, registration studies 2301 (NCT00076336) treated with Lamivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Group C: LdT Pool 2302/015</title>
          <description>Subjects with either compensated or decompensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Telbivudine. Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
        <group group_id="B9">
          <title>Group C: LAM Pool 2302/015</title>
          <description>Subjects with either compensated or decompensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Lamivudine. Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
        <group group_id="B10">
          <title>Group C: Other Feeder Studies</title>
          <description>Patients with either compensated or decompensated chronic hepatitis B, from 2401 (NCT00115245), 2402 (NCT00132652) and 010 (NCT00124241). Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="667"/>
            <count group_id="B2" value="632"/>
            <count group_id="B3" value="123"/>
            <count group_id="B4" value="206"/>
            <count group_id="B5" value="56"/>
            <count group_id="B6" value="26"/>
            <count group_id="B7" value="23"/>
            <count group_id="B8" value="66"/>
            <count group_id="B9" value="57"/>
            <count group_id="B10" value="13"/>
            <count group_id="B11" value="1869"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="27"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="325"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="31"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="520"/>
                    <measurement group_id="B2" value="490"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="153"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="46"/>
                    <measurement group_id="B9" value="43"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="1436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>To Longitudinally Assess the Longer-term Antiviral Efficacy Achieved With Telbivudine Treatment</title>
        <time_frame>52 weeks, 104 weeks, 156 weeks, 208 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Longitudinally Assess the Clinical Efficacy of Longer-term Treatment With Telbivudine</title>
        <time_frame>52 weeks, 104 weeks, 156 weeks, 208 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Longitudinally Assess the Durability of HBeAg Responses Achieved With Telbivudine Treatment and Other Previous Treatments in Patients</title>
        <time_frame>52 weeks, 104 weeks, 156 weeks, 208 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Longitudinal Frequency of Virologic Breakthrough and Characterize the Associated Mutations in the HBV Polymerase Gene in HBV DNA Amplified From Sera of Patients With Virologic Breakthrough</title>
        <time_frame>52 weeks, 104 weeks, 156 weeks, 208 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Maintained Therapeutic Response [Group A: LdT Pool 2302/015]</title>
        <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
        <time_frame>156 weeks, 208 weeks (from feeder study baseline)</time_frame>
        <population>Per protocol (PP) population. The PP analysis was done on separately for the HBeAg-positive and HBeAg-negative subpopulation (status at feeder baseline). n = the number of HBeAg-positive/HBeAg-negative patients who were eligible for maintained therapeutic response.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A : LdT Pool 2302/015</title>
            <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks. The total telbivudine treatment time starting from feeder study baseline to the end of the on-treatment period in study 2303 was 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Maintained Therapeutic Response [Group A: LdT Pool 2302/015]</title>
          <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
          <population>Per protocol (PP) population. The PP analysis was done on separately for the HBeAg-positive and HBeAg-negative subpopulation (status at feeder baseline). n = the number of HBeAg-positive/HBeAg-negative patients who were eligible for maintained therapeutic response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Positive: week 156 (n=338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="61.9" upper_limit="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Positive: week 208 (n=252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="67.9" upper_limit="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 156 (n=197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" lower_limit="75.6" upper_limit="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 208 (n=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" lower_limit="80.2" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Maintained Therapeutic Response [Group A: LAM Pool 2302/015]</title>
        <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
        <time_frame>52 weeks, 104 weeks</time_frame>
        <population>Per protocol (PP) population. The PP analysis was done separately for the HBeAg-positive and HBeAg-negative subpopulation (status at feeder baseline). n = the number of HBeAg-positive/HBeAg-negative patients who were eligible for maintained therapeutic response.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A : LAM Pool 2302/015</title>
            <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Lamivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Maintained Therapeutic Response [Group A: LAM Pool 2302/015]</title>
          <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
          <population>Per protocol (PP) population. The PP analysis was done separately for the HBeAg-positive and HBeAg-negative subpopulation (status at feeder baseline). n = the number of HBeAg-positive/HBeAg-negative patients who were eligible for maintained therapeutic response.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Positive: week 52 (n=338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" lower_limit="54.6" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Positive: week 104 (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" lower_limit="55.2" upper_limit="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 52 (n=182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="74.3" upper_limit="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 104 (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="70.6" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Maintained Therapeutic Response [Group A: Feeder Studies 2401/2402/010]</title>
        <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
        <time_frame>52 weeks, 104 weeks</time_frame>
        <population>Per protocol (PP) population. The PP analysis was done on the PP population, separately for the HBeAg-positive and HBeAg-negative subpopulation (status as feeder baseline). n = the number of HBeAg-positive/HBeAg-negative patients who were eligible for maintained therapeutic response.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Feeder Study 2401</title>
            <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase IIIb, registration study CLDT600A2401 (NCT00115245) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Feeder Study 2402</title>
            <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase IIIb, registration study CLDT600A2402 (NCT00132652) and treated with Lamivudine or Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Feeder Study 010</title>
            <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B were from phase IIb study NV-02B-010 (NCT00124241) of telbivudine, lamivudine or the combination of both agents. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Maintained Therapeutic Response [Group A: Feeder Studies 2401/2402/010]</title>
          <description>The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA &lt; 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
          <population>Per protocol (PP) population. The PP analysis was done on the PP population, separately for the HBeAg-positive and HBeAg-negative subpopulation (status as feeder baseline). n = the number of HBeAg-positive/HBeAg-negative patients who were eligible for maintained therapeutic response.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Positive: 52 week (n = 103, 79, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" lower_limit="68.4" upper_limit="85.3"/>
                    <measurement group_id="O2" value="35.4" lower_limit="25.0" upper_limit="47.0"/>
                    <measurement group_id="O3" value="69.8" lower_limit="53.9" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Positive: 104 week (n = 66, 15, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="70.4" upper_limit="90.2"/>
                    <measurement group_id="O2" value="46.7" lower_limit="21.3" upper_limit="73.4"/>
                    <measurement group_id="O3" value="76.7" lower_limit="57.7" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: 52 week (n = 0, 37, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">In per protocol population, all participants from feeder study 2401 are HBeAg-positive. So, no analysis was done at week 52.</measurement>
                    <measurement group_id="O2" value="54.1" lower_limit="36.9" upper_limit="70.5"/>
                    <measurement group_id="O3" value="NA">In per protocol population, all participants from feeder study 010 are HBeAg-positive. So, no analysis was done at week 52.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: 104 week (n = 0, 10, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">In per protocol population, all participants from feeder study 2401 are HBeAg-positive. So, no analysis was done at week 104.</measurement>
                    <measurement group_id="O2" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O3" value="NA">In per protocol population, all participants from feeder study 010 are HBeAg-positive. So, no analysis was done at week 104.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Maintained Clinical Response [Group B: LdT 2301]</title>
        <description>Maintained clinical response is defined as achievement of serum HBV DNA &lt; 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient’s baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation.</description>
        <time_frame>156 weeks, 208 weeks (from feeder study baseline)</time_frame>
        <population>Per protocol (PP) population. The PP analysis was done on the overall PP population and separately for the HBeAg-positive and HBeAg-negative subpopulation (status at feeder baseline). n = the number of patients who were eligible for maintained clinical response.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B : LdT 2301</title>
            <description>Subjects with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B from phase III pivotal, registration study 2301 (NCT00076336) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks. The total telbivudine treatment time starting from feeder study baseline to the end of the on-treatment period in study 2303 was 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Maintained Clinical Response [Group B: LdT 2301]</title>
          <description>Maintained clinical response is defined as achievement of serum HBV DNA &lt; 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient’s baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation.</description>
          <population>Per protocol (PP) population. The PP analysis was done on the overall PP population and separately for the HBeAg-positive and HBeAg-negative subpopulation (status at feeder baseline). n = the number of patients who were eligible for maintained clinical response.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Positive: week 156 (n= 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="39.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Positive: week 208 (n= 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="2.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 156 (n= 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 208 (n= 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="29.0" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Week 156 (n= 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.9" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Week 208 (n= 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="34.9" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Maintained Clinical Response [Group B: LAM 2301]</title>
        <description>Maintained clinical response is defined as achievement of serum HBV DNA &lt; 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient’s baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation.</description>
        <time_frame>52 weeks,104 weeks</time_frame>
        <population>Per protocol (PP) population. The PP analysis was done on the overall PP population and separately for the HBeAg-positive and HBeAg-negative subpopulation (status at feeder baseline). n = the number of patients who were eligible for maintained clinical response.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B : LAM 2301</title>
            <description>Subjects with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B from phase III pivotal, registration studies 2301 (NCT00076336) treated with Lamivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Maintained Clinical Response [Group B: LAM 2301]</title>
          <description>Maintained clinical response is defined as achievement of serum HBV DNA &lt; 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient’s baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation.</description>
          <population>Per protocol (PP) population. The PP analysis was done on the overall PP population and separately for the HBeAg-positive and HBeAg-negative subpopulation (status at feeder baseline). n = the number of patients who were eligible for maintained clinical response.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Positive: week 52 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="39.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Positive: week 104 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="2.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 52 (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="39.9" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 104 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="47.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: week 52 (n= 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.9" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: week 104 (n= 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="54.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Therapeutic Response [Group C: LdT Pool and LAM Pool (2302/015)]</title>
        <description>The primary efficacy endpoint for Group C patients was the percentage of patients with sustained therapeutic response (defined as HBV DNA &lt; 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
        <time_frame>52 weeks,104 weeks</time_frame>
        <population>The per protocol population. n= is the number of HBeAg-positive/HBeAg-negative patients from per protocol population who achieved maintained response at the end of treatment and had off-treatment assessment to determine the sustained response at that time point or lost sustained response before the off-treatment timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group C : LdT Pool 2302/015</title>
            <description>Subjects with either compensated or decompensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Telbivudine. Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
          </group>
          <group group_id="O2">
            <title>Group C: LAM Pool 2302/015</title>
            <description>Subjects with either compensated or decompensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Lamivudine. Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Therapeutic Response [Group C: LdT Pool and LAM Pool (2302/015)]</title>
          <description>The primary efficacy endpoint for Group C patients was the percentage of patients with sustained therapeutic response (defined as HBV DNA &lt; 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is ALT within normal limits for a patient with an elevated ALT level (&gt;1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.</description>
          <population>The per protocol population. n= is the number of HBeAg-positive/HBeAg-negative patients from per protocol population who achieved maintained response at the end of treatment and had off-treatment assessment to determine the sustained response at that time point or lost sustained response before the off-treatment timepoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAg Positive: week 52 (n= 53, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" lower_limit="55.7" upper_limit="81.7"/>
                    <measurement group_id="O2" value="73.8" lower_limit="58.0" upper_limit="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Positive: week 104 (n= 42, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="41.0" upper_limit="72.3"/>
                    <measurement group_id="O2" value="62.5" lower_limit="43.7" upper_limit="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 52 (n= 3, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O2" value="80.0" lower_limit="28.4" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg Negative: week 104 (n= 3, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Therapeutic Response [Group C: Other Feeder Studies]</title>
        <description>The primary efficacy endpoint for Group C (other feeder studies) was the percentage of patients with sustained therapeutic response (defined as HBV DNA &lt; 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up.
Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive study drug except in case of patients who relapsed and reinitiated treatment. No statistical summary was performed , only patient listing was generated.</description>
        <time_frame>52 weeks,104 weeks</time_frame>
        <population>In &quot;Group C: other feeder study&quot; reporting group, there were only 13 patients; hence, no summary statistics were performed. Only listings were generated.</population>
        <group_list>
          <group group_id="O1">
            <title>Group C : Other Feeder Studies</title>
            <description>Patients with either compensated or decompensated chronic hepatitis B, from 2401 (NCT00115245), 2402 (NCT00132652) and 010 (NCT00124241). Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Therapeutic Response [Group C: Other Feeder Studies]</title>
          <description>The primary efficacy endpoint for Group C (other feeder studies) was the percentage of patients with sustained therapeutic response (defined as HBV DNA &lt; 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up.
Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive study drug except in case of patients who relapsed and reinitiated treatment. No statistical summary was performed , only patient listing was generated.</description>
          <population>In &quot;Group C: other feeder study&quot; reporting group, there were only 13 patients; hence, no summary statistics were performed. Only listings were generated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All safety analyses were performed on the safety populations defined for each reporting group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A : LdT Pool 2302/015</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks. The total telbivudine treatment time starting from feeder study baseline to the end of the on-treatment period in study 2303 was 208 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Group A : LAM Pool 2302/015</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Lamivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Group A: Feeder Study 010</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B were from phase IIb study NV-02B-010 (NCT00124241) of telbivudine, lamivudine or the combination of both agents. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Group A: Feeder 2401</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase IIIb, registration study CLDT600A2401 (NCT00115245) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Group A: Feeder 2402</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B from phase IIIb, registration study CLDT600A2402 (NCT00132652) and treated with Lamivudine or Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Group B: LdT 2301</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B from phase III pivotal, registration study 2301 (NCT00076336) treated with Telbivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks. The total telbivudine treatment time starting from feeder study baseline to the end of the on-treatment period in study 2303 was 208 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Group B: Lam 2301</title>
          <description>Subjects with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B from phase III pivotal, registration studies 2301 (NCT00076336) treated with Lamivudine. Telbivudine 600 mg by mouth (p.o.) daily for 104 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Group C : LdT Pool 2302/015</title>
          <description>Subjects with either compensated or decompensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Telbivudine. Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
        <group group_id="E9">
          <title>Group C: Lam Pool 2302/015</title>
          <description>Subjects with either compensated or decompensated chronic hepatitis B from phase III pivotal, registration studies 2302 (NCT00057265) and 015 (NCT00131742) treated with Lamivudine. Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
        <group group_id="E10">
          <title>Group C : Other Feeder Studies</title>
          <description>Patients with either compensated or decompensated chronic hepatitis B, from 2401 (NCT00115245), 2402 (NCT00132652) and 010 (NCT00124241). Patients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive any study drug except in case of patients who relapsed and reinitiated treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>APLASIA PURE RED CELL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VESTIBULAR NEURONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PERITONEAL ADHESIONS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>APLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CONCOMITANT DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CHRONIC HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DENGUE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>EPIGLOTTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>LEPTOSPIROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>JOINT LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>JOINT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>TOOTH INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DIABETIC HYPEROSMOLAR NON-KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>POLYMYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACOUSTIC NEUROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DIFFUSE LARGE B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NASAL NEOPLASM BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PROLACTINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>THYROID GLAND CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DIABETIC HYPEROSMOLAR COMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEPATIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ABORTION MISSED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HYPOMANIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHRITIS PROLIFERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE UROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PROSTATIC HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>VULVAL ANGIOKERATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CATARRH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NASAL MUCOSAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NASAL TURBINATE ABNORMALITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABORTION INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>FRACTURE TREATMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>BLEEDING VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="318" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="309" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="40" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="33" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ABDOMINAL SYMPTOM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PITTING OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BODY TINEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>TINEA VERSICOLOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>JOINT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HBV DNA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS NON-INSULIN-DEPENDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MUSCLE CRAMP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>HEPATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>GLOMERULONEPHRITIS PROLIFERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PALMAR ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SPIDER NAEVUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>EYE OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="626"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

